Dermatology
Partner With Us
Advertisement
Conexiant chevron_right Dermatology chevron_right Predictive Rituximab Protocol Reduces Pemphigus Relapse Risk
From the Journals

Predictive Rituximab Protocol Reduces Pemphigus Relapse Risk

French multicenter study demonstrates targeted rituximab maintenance therapy guided by clinical and serological markers cuts early pemphigus relapse rates from 17.6% to 2.6%

Conexiant
article Full Article subject Summary summarize Notecard
  1. Predictive factors can guide additional rituximab treatment in pemphigus patients to reduce early relapse rates.
  2. Key predictors of relapse include a baseline PDAI score ≥ 45, DSG1 antibodies > 20 IU/mL, and/or DSG3 antibodies > 130 IU/mL at 3 months.
  3. Patients with predictors who received additional rituximab had a relapse rate of 0%.
  4. The study findings validate the use of predictors of early relapse after an initial cycle of rituximab in patients with pemphigus.
  5. A randomized clinical trial is currently underway to further test this strategy.

Daily News

Stay up to date with the latest clinical headlines and other information tailored to your specialty.